Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study.
Benjamin W Van TassellVirginia MihalickGeorgia ThomasAmr MarawanAzita H TalasazJuan LuLe KangAmy LaddJuan Ignacio DamonteDave L DixonRoshanak MarkleyJeremy TurlingtonEmily FedermannMarco Giuseppe Del BuonoGiuseppe Biondi-ZoccaiJustin M CanadaRoss ArenaAntonio AbbatePublished in: Journal of translational medicine (2022)
The trial was registered prospectively with ClinicalTrials.gov on Jan 8, 2019, identifier NCT03797001.
Keyphrases